BioEngine Raises Another RMB 200 Million, Continues to Promote the "Made in China" Serum-Free Culture Media

Legend Capital said,

We are pleased to have Legend Capital as the lead investor in this round of financing. As one of the important core raw materials in the upstream of innovative biotechnology, such as biopharmaceuticals, vaccines, gene, and cell therapy, cell culture media plays an irreplaceable role in supporting and guaranteeing, and the need to solve the "containment" risk is becoming more and more urgent, with huge development space. Relying on the academic, technical, and application accumulation of the "only Chinese national team" of cell culture for more than 30 years, Bechtel has continuously innovated and made breakthroughs and realized the real meaning of independent control and large-scale localization in the fields of formula design, production process, and supply chain system, and its products and services are widely recognized. Legend Capital, as a leading domestic venture capital institution, aims to help companies grow and innovate through capital and management. Legend has always focused on innovation and growth investments in upstream life science-related industries and has built an industry ecosystem covering innovative medicine, biotechnology, upstream core raw materials, and equipment. We expect Betsy to leverage this round of financing to continuously optimize the technology platform and service system, accelerate product upgrade and commercialization promotion, and lead the development of the core raw material and equipment industry. We will also closely link with customers and partners to enhance the value of the industry, gradually form a global brand influence, and help China's biopharmaceutical industry take off.

Addor Capital said,

Culture media is the blood of biopharmaceuticals, and BioEngine is one of the companies with the deepest technology accumulation, the most abundant product pipeline, and the largest industrialization scale in China. Currently, the products of BioEngine have covered hundreds of customers, ranging from animal vaccines, human vaccines, antibody drugs, gene/cell therapies, etc. Bechtel has assisted several downstream customers to complete the registration and commercialization of their products. Addor Capital is honored to participate in this investment and we will continue to support the development of the company together we will assist the company to better serve domestic-related companies.

Tsing Song Capital said,

We are very pleased to participate in this round of financing. As one of the most important upstream raw materials in the biopharmaceutical field, culture media is also a key consumable that faces the risk of "containment" and has great potential for development. In addition to having the leading technology level of cell culture media and upstream process development of biopharmaceuticals in China, BioEngine has also been widely recognized by industry users for its culture media manufacturing and quality management level. In recent years, BioEngine has introduced world-class production technology and an international advanced quality management system to realize the scale, informatization, and internationalization of domestic culture media production, and has grown into a benchmark enterprise of high-quality culture media manufacturers in China. Together with our strategic partners, we continue to focus on and support the development and innovation of the upstream supply chain to provide a safe and high-quality development foundation for the biopharmaceutical industry. We expect that with the support of this round of financing, BioEngine will accelerate the technology upgrade and commercialization of its products and services, build an industry-leading technology platform and service system, and provide customers with more high-quality, safe, and stable products and services.

Hankang Capital said,

Innovative antibodies, vaccines, and cell therapy products continue to create benefits for patients and are one of the main driving forces behind the rapid development of China's biopharmaceutical industry. Serum-free medium is a key raw material for biopharmaceutical production, and the R&D innovation and industrialization of cell culture technology and medium brands and the gradual localization in the industry are also in line with the direction of national support for specialized and new industries. Since the investment of Han Kang Capital, Bechtel has continued to innovate and develop, and its ability and strength of manufacturing high-performance serum-free culture medium with international quality has been fully tested by the market and highly recognized by customers. We are grateful to the new investors for joining us and working together with our team to promote the "Intelligent Manufacturing in China" of key raw materials of international quality.